HomeCompareBNGRF vs MRK

BNGRF vs MRK: Dividend Comparison 2026

BNGRF yields 2.54% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNGRF wins by $188.46M in total portfolio value
10 years
BNGRF
BNGRF
● Live price
2.54%
Share price
$70.30
Annual div
$1.79
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$188.51M
Annual income
$175,274,341.61
Full BNGRF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — BNGRF vs MRK

📍 BNGRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNGRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNGRF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNGRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNGRF
Annual income on $10K today (after 15% tax)
$216.19/yr
After 10yr DRIP, annual income (after tax)
$148,983,190.37/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, BNGRF beats the other by $148,974,861.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNGRF + MRK for your $10,000?

BNGRF: 50%MRK: 50%
100% MRK50/50100% BNGRF
Portfolio after 10yr
$94.28M
Annual income
$87,642,069.87/yr
Blended yield
92.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BNGRF
No analyst data
Altman Z
4.0
Piotroski
7/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNGRF buys
0
MRK buys
0
No recent congressional trades found for BNGRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNGRFMRK
Forward yield2.54%2.76%
Annual dividend / share$1.79$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$188.51M$56.8K
Annual income after 10y$175,274,341.61$9,798.13
Total dividends collected$187.50M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BNGRF vs MRK ($10,000, DRIP)

YearBNGRF PortfolioBNGRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,209$508.68$11,206$366.19+$3.00BNGRF
2$13,059$1,065.72$12,650$502.35+$409.00BNGRF
3$16,294$2,320.84$14,407$694.19+$1.9KBNGRF
4$22,847$5,412.62$16,585$967.82+$6.3KBNGRF
5$38,632$14,185.99$19,342$1,363.89+$19.3KBNGRF
6$86,173$44,835.87$22,913$1,947.19+$63.3KBNGRF
7$279,139$186,934.18$27,662$2,823.89+$251.5KBNGRF
8$1,430,521$1,131,842.56$34,159$4,173.35+$1.40MBNGRF
9$12,372,578$10,841,920.29$43,337$6,308.80+$12.33MBNGRF
10$188,513,000$175,274,341.61$56,776$9,798.13+$188.46MBNGRF

BNGRF vs MRK: Complete Analysis 2026

BNGRFStock

Savencia SA produces dairy products in France and internationally. It offers cheese; butters and creams for the retail market and catering professionals; and dairy ingredients for the food, nutrition, and healthcare industries. The company was formerly known as Bongrain SA and changed its name to Savencia SA in April 2015. Savencia SA was founded in 1956 and is based in Viroflay, France.

Full BNGRF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BNGRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNGRF vs SCHDBNGRF vs JEPIBNGRF vs OBNGRF vs KOBNGRF vs MAINBNGRF vs JNJBNGRF vs ABBVBNGRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.